Stock comparison
Haemonetics
Anbio Biotechnology
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
NNNN
Anbio Biotechnology
Market cap
$1.43B
Sector
Healthcare
Overall winner
Anbio Biotechnology NNNN
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | NNNN | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 58C | HAE |
| Benjamin Graham | 85A | 87A | NNNN |
| Philip Fisher | 60C | 89A | NNNN |
| Peter Lynch | 54C | 95A | NNNN |
| Joel Greenblatt | 31F | 36D | NNNN |
| Charlie Munger | 54D | 73C | NNNN |
| Terry Smith | 55D | 72C | NNNN |
Side-by-side metrics
| Metric | HAE | NNNN |
|---|---|---|
| Market cap | $2.98B | $1.43B |
| P/E (TTM) | 24.8x | 171.9x |
| EV/EBIT | 14.1x | 212.9x |
| ROIC (TTM) | 8.37% | 21.48% |
| Gross margin | 55.74% | 87.06% |
| Net margin | 7.29% | 73.75% |
| Revenue CAGR 5y | 7.65% | 18.21% |
| EPS CAGR 5y | 24.62% | 58.42% |
| Debt / Equity | 1.5x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 212.9x+93%
- P/E (TTM)24.8xvs 171.9x+86%
- Market cap$2.98Bvs $1.43B+52%
NNNN leads on
- Debt / Equity-vs 1.5x+100%
- Net margin73.75%vs 7.29%+90%
- ROIC (TTM)21.48%vs 8.37%+61%
- Revenue CAGR 5y18.21%vs 7.65%+58%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.